NCT01319370CompletedPhase 2
Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks
Natalie GARCIA BARTELS1 site in 1 country70 target enrollmentStarted: November 2010Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- Change of target area non-vellus hair count in the temple region (t-TAHC) [n/cm²] compared to baseline after 24 weeks
Study Overview
Brief Summary
The current study aims to show efficacy of twice daily application of 5% Minoxidil Topical Foam (MTF) formulation compared to placebo in the temple region of male patients with androgenetic alopecia after 24 weeks as well as to gain long-term data on the efficacy and safety of 5% MTF in male subjects with AGA in temple and vertex region, over a period of 2 years. Objective and subjective efficacy measures will be compared to baseline. Moreover, all patients will get the equal treatment and measurements in the vertex region to enable comparison of the efficacy of 5% Minoxidil Topical Foam in the temples not only to baseline but also to vertex region. Additionally safety assessments will be performed throughout the whole study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male, age 18 to 70 year old, in general good health
- •Exhibits male AGA based on a discernable hair loss in temple and vertex region rating Hamilton-Norwood Scale III vertex to VI (See Appendix 1)
- •Subjects who give their consent to the study after thorough explanation and who personally signed and dated the informed consent document indicating that the subject, has been informed of all pertinent aspects of the trial
- •Willing to maintain the same hairstyle, hair length and hair color throughout the study
- •Subjects who are willing and able to comply with scheduled visits, treatment plan, mini-tattoo and other trial procedures
- •Accepting the Information form plus accepting and signing the Informed Consent form
Exclusion Criteria
- •Known to be hypersensitive to minoxidil, hair dye (p-phenylenediamine), tattoo ink, fragrances, hair gel or any vehicle components
- •Current or 4 weeks dated back use of medical shampoos or solutions which include Ketoconazole or the like (e. g. Terzolin®) in the target region interfering with the CTM or examination method
- •Current or 3 months dated back use of topical treatment in the target regions taken for more then 2 consecutive weeks interfering with the CTM (topical corticosteroids, aminexil, minoxidil, estrogens)
- •Current or 3 months dated back use of systemic treatment (drugs or dietary supplement) taken for more than 2 consecutive weeks interfering with the CTM or examination method (beta blocker, cimetidine, diazoxide, isotretionin, corticosteroids, vitamin A intake above 10000 IU per day)
- •Current or 12 months dated back use of Finasteride (Propecia®, FinaHair®, etc.), Dutasteride or a similar product
- •Within past 12 months undergoing chemotherapy or receiving cytotoxic agents as well as radiation and/or laser/surgical therapy of the scalp
- •Current or prior enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation
- •Presence of hair transplants, hair weaves or non-breathable wigs and hair bonding
- •Current or 2 months dated back severe diet or presenting a history of eating disorder
- •Any dermatological disorders of the scalp in the target region with the possibility of interfering with the CTM or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars or scalp atrophy
- •Untreated persisting hypertension
- •Active hair loss or history within the past 3 months including diffuse telogen effluvium, alopecia areata, scarring alopecia
- •Other severe, acute or chronic medical condition that may lead to hair loss or interfere with the interpretation of trial results (e. g. untreated hypothyroidism)
- •Individuals who are institutionalized by court or regulatory order
Arms & Interventions
vehicle of 5% Minoxidl topical foam
Placebo Comparator
vehicel foam in twice daily application in temple and vertex region
Intervention: vehicle of 5% Minoxidil topical foam (Drug)
5% Minoxidil topical foam
Active Comparator
5% Minoxidil topical in twice daily application in temple and vertex region
Intervention: Minoxidil (Drug)
Outcomes
Primary Outcomes
Change of target area non-vellus hair count in the temple region (t-TAHC) [n/cm²] compared to baseline after 24 weeks
Time Frame: Baseline, week 8, week 16, week 24, week 52, week 76, week 104
Secondary Outcomes
- Assessing the investigational products safety by means of clinical examination (local intolerance, AE, SAE)(every visit from baseline to week 104)
- Change of t-TAHC, v-TAHC, t-TAHW and v-TAHW comparing 5% MTF and Placebo Topical Foam (plaTF) groups(Baseline, week 8, week 16, week 24, week 52, week 76, week 104)
- Change of cumulative hair width in non-vellus hair in temple and vertex region (t-TAHW; v-TAHW) [mm/cm²] compared to baseline after 24, 52, 76 and 104 weeks(Baseline, week 8, week 16, week 24, week 52, week 76, week 104)
- Global expert panel and subjects' rating change in scalp coverage: week 24 compared to baseline, week 104 compared to baseline and week 104 compared to week 24 via assessment of global temple and vertex photographs(Baseline, week 8, week 16, week 24, week 52, week 76, week 104)
Investigators
Natalie GARCIA BARTELS
PD
Charite University, Berlin, Germany
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair LossAndrogenetic AlopeciaNCT00151515Johnson & Johnson Consumer and Personal Products Worldwide352
Completed
Phase 2
Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida InfectionsCandidiasisNCT01102387Almirall, S.A.137
Recruiting
Phase 3
A camparative study effectiveness topical minoxidil nanosuspention and minoxidil %2 solution in the treatment of alopecia androgeneticIRCT20180120038450N1Kermanshah University of Medical Sciences140
Recruiting
Early Phase 1
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast CancerAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Endocrine Therapy-Induced AlopeciaPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8NCT05417308Ohio State University Comprehensive Cancer Center50
Completed
Not Applicable
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic AlopeciaMale Pattern of Hair Loss, Androgenic AlopeciaNCT02460289Galderma R&D63